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Background: Whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), or
both are commonly employed in the treatment of limited brain metastases in the initial
or recurrent setting. Hypofractionated partial volume irradiation is also employed, how-
ever, published experience using helical TomoTherapy (HT) for this purposes is limited.
We reviewed our institutional experience to assess patient selection factors, fractionation
scheme, and outcomes associated with this technique.
Methods: A retrospective chart review was performed to evaluate patients treated with
partial volume hypofractionated HT-based IMRT for brain metastases at our institution.
Results:Thirteen patients (7M/6F, median age 62, median KPS 90) with a limited (1–9) num-
ber of brain metastases in the primary or recurrent setting were identified. Primary malig-
nancies included colorectal (3), NSCLC (5), RCC (1), breast (1), melanoma (1), uterine (1),
and ovarian (1).The median time from initial diagnosis to brain metastases was 20.7 months
(range 0–61.3). Treatment was delivered to intact metastases in six patients, to a single
resection cavity in six patients, and to both in one patient. A total of 27 lesions were treated.
The median number of intact metastases treated was two (range 1–9). Previous treatments
included WBRT (5), WBRT+SRS (3), SRS alone (1), and none (4). The most common
fractionation schemes were 25 Gy in five fractions and 27.5 Gy in five fractions to each
lesion. At a median of 6 months follow up (range 1.26–20.13) afterTomoTherapy, 10 patients
were deceased, 2 were alive, and 1 was lost to follow up. Systemic progression occurred
in seven patients and intracranial progression occurred in five. The median intracranial
progression free survival and overall survival afterTomoTherapy was 6.3 months. Freedom
from local failure for treated lesions was 71% and 59% at 6 and 12 months.
Conclusion: TomoTherapy-based hypofractionated radiotherapy to a limited number of
metastatic lesions is associated with acceptable intracranial disease control and survival
outcomes and represents a viable treatment option in the primary and recurrent setting
for select patients.
Keywords: brain metastases, radiotherapy, fractionated SRS, TomoTherapy, hypofractionated radiotherapy,
oligometastases
INTRODUCTION
Brain metastases as a systemic manifestation of cancers from
various primary sites and histologies has historically implied an
extremely poor prognosis with survival measured in weeks in
untreated cases (1). Traditionally, the use of whole-brain radi-
ation therapy (WBRT) has been the mainstay of treatment for
brain metastases with an improvement in survival estimated on
the order of several months (2). Improvements in the care of
patients with metastatic disease in several domains including
advances in systemic therapies such as combination chemother-
apy and targeted agents, improvements in control of the pri-
mary lesion, and advances in radiotherapeutic modalities has
resulted in a proportion of patients surviving with brain metas-
tases for a longer duration (3). In addition, the stratification
of patients according to prognostic factors including age, per-
formance status, and control of primary disease has attempted
to identify patients with potentially durable survival (4). The
concept of “oligometastatic” brain disease, which is variably
defined, but often on the order of 1–5 brain metastases, has
led to alternative management considerations other than the
routine application of WBRT as a sole modality (5, 6). Given
that reports have described select patients with brain metas-
tases with survival on the order of several years, the manage-
ment of oligometastatic brain disease reflects a balance between
optimal intracranial disease control and potential toxicities or
adverse long term sequelae of treatment. In addition, with con-
tinued improvements in extracranial disease control and systemic
therapy options, many patients are faced with the problem of
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recurrent intracranial disease in the setting of prior intracranial
therapy.
At the present time, there are wide array of modalities employed
in the treatment of oligometastatic brain metastases both in
the up-front and recurrent setting, each with their own unique
potential advantages and pitfalls (7). Options include surgi-
cal resection, single fraction radiosurgery, both linac-based and
Gamma Knife based, WBRT, and various combinations thereof. A
recent ASTRO consensus statement highlights the relative mer-
its and adversities of these modalities, all of which are con-
sidered appropriate options in different circumstances (8). A
more recent management trend with a limited but growing
experience, however, is the use of hypofractionated local ther-
apy for limited brain metastases, which has been given vari-
ous designations including fractionated stereotactic radiosurgery
(FSRS), hypofractionated conformal stereotactic radiation ther-
apy (HCSRT), and hypofractionated stereotactic radiosurgery
(HSRS), and has employed various modalities including linac
cone, linac IMRT, linac 3D, and Cyber Knife, as well as non-
invasive vs. invasive stereotactic positioning systems (9–17).
Potential advantages of the hypofractionated technique, partic-
ularly for larger intracranial targets, include the patient con-
venience of a relatively few number of treatments, the normal
tissue sparing achieved through focal irradiation, as well as the
improved normal tissue tolerance of high dose radiation through
fractionation (18).
In comparison to linac-based methods, the use of helical
TomoTherapy (HT) is less reported for the treatment of brain
metastases. HT is a unique IMRT delivery system capable of
achieving highly conformal dose distributions with good cover-
age of intracranial targets and normal tissue sparing (19). Several
reports have described the use of HT in the treatment of brain
metastases both as an integrated boost within a simultaneous
WBRT plan, and alone as a focal treatment (20–24). In addi-
tion, previous dosimetric investigations have indicated that HT
possesses favorable dosimetric properties for the application of
focal irradiation of metastatic lesions in comparison with more
commonly used modalities including linac and Gamma Knife
radiosurgical systems (25–27).
At our institution, patients with limited intracranial metastases
or a resection cavity deemed eligible for stereotactic radiosurgery
(SRS) are most commonly treated with a single fraction using
Gamma Knife radiosurgery if the lesion is amenable to this type
of treatment based on size and location criteria. Due to concerns
of toxicity, larger target lesions (typically >3 cm diameter) may
not be recommended for single fraction SRS on a provider depen-
dent basis. In addition for recurrent lesions in the setting of prior
WBRT, repeat WBRT may be avoided due to toxicity concerns by
focal treatment to recurrent lesions. The use of hypofractionated
radiotherapy with TomoTherapy therefore represents an option
for select patients when local control of limited intracranial dis-
ease not amenable to single fraction SRS is desired while avoiding
initial or repeat WBRT. The purpose of this study was to report our
institutional experience with the use of HT for focal irradiation
alone to intact brain metastases or the post-operative resection
cavity for patients with oligometastatic disease both in the initial
and recurrent setting.
MATERIALS AND METHODS
PATIENT SELECTION
Patients treated with hypofractionated TomoTherapy-based focal
irradiation for brain metastases were identified for this retrospec-
tive review through a query of the departmental electronic medical
record. Patients were eligible for analysis if they had a histologi-
cally documented primary malignancy of any solid tumor with
confirmed brain metastases, either histologically or radiograph-
ically. All patients were treated with hypofractionated HT-based
IMRT for 1–9 lesions, which include intact brain metastases or
a post-operative resection cavity. Hypofractionated therapy con-
sisted of treatments delivered to focal brain volumes only (i.e., not
as a component of WBRT) with 4–10 fractions of 250–550 cGy
per fraction. Two of the patients treated at 2.5 Gy per fraction
had numerous target lesions (nine and four) prompting concern
over the volume of brain tissue that would have been irradiated at
higher dose per fraction, and one patient was intended to undergo
treatment at 5 Gy per fraction but elected to proceed with treat-
ment at 2.5 Gy per fraction. These patients were included in this
analysis due to the fact that the intent of treatment was to deliver
focal irradiation to specified lesions as opposed to repeat WBRT.
Treatments for all patients in this study were completed between
2/2009 and 10/2013. No standard selection criteria were employed
for the determination to use HT-based focal irradiation; this was
practitioner dependent on a case-by-case basis. In general, how-
ever patients selected for this modality were not eligible for single
fraction SRS due to size constraints of the target lesion(s). All
aspects of this retrospective review were approved by the IRB.
RADIOTHERAPY PLANNING AND DELIVERY
All patients were treated with HT-based IMRT on a TomoTher-
apy Hi-Art unit using TomoPlan treatment planning software
(TomoTherapy, Madison, WI, USA). Treatment planning was
based on thin slice kV CT simulation images of the brain reg-
istered to MR images acquired in the treatment position using a
thermoplastic mask for immobilization. Target delineation con-
sisted of identification of the primary lesion(s) using the MRI
T1+C sequence to identify the GTV with a 3 mm PTV expan-
sion. The most common fractionation schemes were 25 Gy in five
fractions of 500 cGy per fraction, and 27.5 Gy in five fractions of
550 cGy per fraction. All treatments were designed to deliver the
prescription dose to 95% of the PTV volume. Treatments deliver-
ing more than 400 cGy per fraction were delivered on alternating
days as opposed to consecutively.
FOLLOW UP AND STATISTICAL ANALYSIS
After radiotherapy completion, all patients were followed up at
approximately 3-month intervals with repeat MRI imaging until
death or inability to return for evaluation. During the study period,
11 patients had imaging documented in the medical record within
2 months of death or last follow up, 1 patient had an MRI scan
4.5 months prior to death, and 1 patient had an MRI scan 6 months
prior to death (this patient was entered into hospice approxi-
mately 2 months after this MRI scan however lived 4 months in
hospice care during which time imaging was not performed). The
median time interval between the last imaging and death or last
follow up was 32 days. Overall survival from the completion of
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radiation therapy was defined as the duration from the end of
radiation to death from any cause. Intracranial progression free
survival was defined as the duration from the completion of radi-
ation to progression of disease within the brain or death. Overall
survival from initial diagnosis was defined as the duration from
pathological confirmation of malignancy from any site to death
from any cause. Determination of progressive disease for the pur-
poses of this study was made on the basis of formal radiologic
reports of follow up MRI evaluations. If lesion progression was
described as the most likely description for imaging findings this
was regarded as progression even if histopathologic confirma-
tion or additional subsequent imaging was not available. Survival
analysis was performed using the Kaplan–Meier method. Statis-
tical analysis was performed using MedCalc statistical software
version 12.7 (MedCalc Software, Ostend, Belgium).
RESULTS
PATIENT CHARACTERISTICS AND TREATMENT
Thirteen patients were identified (7M/6F) with a median age of 62
and median KPS of 90. The majority of patients (9/13) had a single
focal lesion (intact metastasis or resection cavity), and 4/13 had
multiple lesions treated simultaneously. A total of 27 metastases
were treated. Six patients were treated for intact lesions, six patients
were treated for post-operative resection cavities, and one patient
has one intact lesion and one resection cavity treated. The median
and mean PTV volume was 20 and 33 cc, respectively (range 2–
96 cc). The most common fractionation schemes were 25 Gy in
five fractions of 500 cGy per fraction, and 27.5 Gy in five fractions
of 550 cGy per fraction. One patient’s plan per patient request
was modified after the first fraction from 500 cGy per fraction to
250 cGy per fraction. Histologic subtypes included colorectal (3),
non-small cell lung cancer (5), renal cell carcinoma (1), breast
(1), melanoma (1), uterine (1), and ovarian (1). Metastases were
located in both cerebral and cerebellar locations. The majority of
patients (9/13) had previously undergone intracranial radiother-
apy including WBRT alone (5), WBRT+ SRS (3), and SRS alone
(1). Four patients had previously undergone no prior intracranial
radiotherapy. Four patients were diagnosed with brain metastases
concurrently with the primary tumor diagnosis, and nine patients
were diagnosed with brain metastases after the initial primary
tumor diagnosis. The median time from initial diagnosis to the
occurrence of brain metastases was 21 months. The primary dis-
ease was stable in 7/13 patients and progressive in 6/13 patients
prior to the start of XRT. The majority of patients (12/13) had
at least one neurologic symptom prior to radiation including
diplopia (1), headache (2), gait ataxia (2), aphasia (1), confu-
sion and memory decline (1), weakness (3), and seizures (2). One
patient was neurologically asymptomatic prior to treatment. The
median follow up period after XRT was 6.2 months (range 1.26–
20.13 months). Patient characteristics are summarized in Table 1.
Representative plans are depicted in Figures 1 and 2.
CONTROL OF INTRACRANIAL DISEASE
Intracranial in-field failure alone was exhibited in two (15%)
patients, intracranial out of field failure alone was exhibited in one
(8%) patient, and both in-field and out of field intracranial failure
was noted in three (23%) patients. In terms of treated lesions, 8 of
27 treated lesions (29.6%) exhibited failure. Seven (54%) patients
did not exhibit any intracranial failure. The median intracranial
failure free survival after XRT was 6.3 months. The 6 and 12-month
freedom from local failure for treated lesions was 71% and 59%.
OVERALL SURVIVAL
The median overall survival from initial diagnosis of malignancy
was 36 months (range 8.5–55 months). The median overall
Table 1 | Patient data table.
Patient Age Sex KPS Histology Time from
Dx to
BM (mo.)
Location of BM # Lesions
treated
Total
dose/#Fx
Prior IC radiotherapy Deceased
1 70 M 100 Colorectal 49 Cerebellar 1 25 Gy/5Fx None Yes
2 51 M 80 NSCLC 0 Multifocal 9 25 Gy/10Fx WBRT 35 Gy Yes
3 65 M 90 NSCLC 73 Left lateral cerebellar 1 20 Gy/5Fx WBRT 37.5 Gy+GK SRS x2 Yes
4 60 M 100 RCC 33 Right ventricle 1 27.5 Gy/5Fx WBRT 37.5 Gy Yes
5 62 M 80 Melanoma 22 Multifocal 4 25 Gy/10Fx WBRT 30 Gy Yes
6 47 F 80 Breast 21 Right parietal 1 5 Gy×1+
25 Gy/10Fx
WBRT 37.5+GK SRS x2 Unknown
7 70 F 90 NSCLC 13 Right temporal-parietal 1 27.5 Gy/5Fx WBRT 37.5 Yes
8 83 F 90 Colorectal 61 Multifocal 3 25 Gy/5Fx None Yes
9 81 M 90 NSCLC 0 Right temporal-parietal 1 27.5 Gy/5Fx GK SRS x1 Yes
10 60 M 80 NSCLC 0 Multifocal 2 25 Gy/5Fx WBRT 30 Gy Yes
11 55 F 100 Colon 0 Right parietal 1 27.5 Gy/5Fx WBRT 37.5 Gy+GK SRSx4 No
12 59 F 80 Uterine
adenocarcinoma
8 Right temporal 1 20 Gy/5Fx None Yes
13 67 F 90 Papillary serous
ovarian
33 Right temporal-parietal 1 27.5 Gy/5Fx None No
Dx, diagnosis; BM, brain metastases; IC, intracranial.
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survival from the completion of TomoTherapy hypofractionated
XRT was 6.3 months (range 1–20 months). The 6 and 12-month
OS rate was 69% and 20%. At the time of analysis, 10 patients were
known to have deceased, 2 patients were known to be alive, and 1
patient was unknown status.
Figure 3 depicts Kaplan–Meier survival curves for OS from
initial diagnosis, OS from the completion of TomoTherapy,
intracranial FFS, and freedom from local failure for treated lesions.
TREATMENT RELATED TOXICITY
Eight of 13 patients had no reported toxicities,2 had alopecia,1 had
nausea, and 1 has nausea with headache. No >grade 3 toxicities
were reported relative to the Common Terminology Criteria for
Adverse Events version 4.0. One patient had hemorrhagic trans-
formation of a treated metastasis with subsequent intracranial
hemorrhage and passed away shortly thereafter.
DISCUSSION
Despite the increasing use of hypofractionated radiosurgical tech-
niques in the management of brain metastases, there is a relative
paucity of reports describing the use of HT for this purpose. The
majority of such reports describe a treatment scheme, which incor-
porates a lesion specific integrated boost within a WBRT plan (20,
22, 28). Less reported however is the use of HT for hypofraction-
ated focal irradiation alone of lesions. Sanghera et al. reported on
FIGURE 1 | Representative screenshots depicting isodose distributions
of a plan delivered to a single intact brain metastasis with conformal
avoidance of the brainstem. The prescription does was 27.5 Gy in five
fractions.
five patients treated with HT who were unwilling or unable to
undergo linac-based SRS and concluded that TomoTherapy rep-
resented a viable alternative (24). Tomita et al. reported on 16
patients with 1–4 brain metastases treated focally to 35 or 37.5 Gy
in 5 fractions of whom 2 developed a local recurrence at the treated
site and 3 developed new intracranial metastases (29). Nagai et al.
reported on a prospective cohort of 54 patients with 128 metas-
tases treated with a 4 fraction technique to 28 Gy using HT with an
overall 1 year LC rate of 91% and a median OS of 7 months (23).
In addition, dosimetric comparison studies have been performed
between HT and other modalities of radiosurgical dose delivery
and have established a rationale for the use of this technique.
In comparison to Gamma Knife SRS, HT-based radiosurgery has
been found to achieve similar target coverage and similar confor-
mity indices, however with a smaller high dose volume but with the
disadvantage of a larger amount of normal tissue irradiation (19,
25, 30). A dosimetric comparison between intensity modulated
radiosurgery and HT for 3–6 brain metastases revealed equivalent
conformity indices, target coverage, and sparing of the organs at
risk between the modalities, however with a higher integral dose
attributed to HT (26).
The present study, although not the largest experience with the
use of TomoTherapy for the focal hypofractionated treatment of
brain metastases, provides further support for the feasibility of
this technique. The intracranial failure free survival of 54% and
the median OS of 6.3 months exhibited in the present analysis are
comparable to the results noted in the previous reports. Important
differences however between the present study and the studies of
Tomita et al. and Nagai et al. must be acknowledged. In particular,
Tomita et al. included patients without any prior intracranial treat-
ments, and Nagai et al. did not allow patients previously treated
with WBRT, where as in the present study the majority of patients
had received prior treatments including WBRT, SRS, or both. In
addition, Nagai et al. restricted lesion size to <3 cm for eligibility
whereas in the present study no such size criteria were employed.
Despite these differences in patient and lesion selection criteria, the
present study supports the use of HT in the treatment of lesions
in the setting of prior radiotherapy or with a target size >3 cm.
Given that lesion size is frequently reported to be correlated
with local control, the larger size of the target volumes treated
in this series may contribute to the relatively lower local control
rate (38% of patients had local failure as a component of failure,
FIGURE 2 | Representative screenshots depicting isodose distributions of a plan delivered to a single post-operative resection cavity. The prescription
dose was 27.5 Gy in five fractions.
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FIGURE 3 | Kaplan–Meier survival curves depicting (A) overall survival from initial diagnosis of malignancy, (B) overall survival from the completion of
TomoTherapy, (C) intracranial failure free survival, and (D) freedom from local failure for treated lesions.
and 29.6% of the treated lesions exhibited failure) than those
reported in other series. In a study of patients treated with single
fraction Gamma Knife SRS, Shiau et al. reported reduced failure
free survival for larger lesions, with lesions <3, 3–10, and >10 cc
exhibiting 1 year local control of 87%, 63%, and 25%, respectively
(31). Aoyama et al. reported that in the setting of hypofraction-
ated SRS, local control for tumors <3 vs. >3 cc was 96% and
59%, respectively (10). Eaton et al. also reported decreased local
control in the hypofractionated setting with an increase in tumor
volume, and reported an overall 1 year local control of 61% and
an intracranial PFS of 55% in a group of patients with a median
PTV volume of 24.5 cc (12). The present series reports a similar
finding of a mean PTV volume of 33 cc with 6 and 12 months
freedom from local failure of 71% and 59%. A tumor with a
diameter of 2 cm (radius of 1 cm) would have a volume of 4.2 cc
assuming the volume is calculated according to V= 4/3pir3. The
mean PTV volume of 33 cc in this series would correspond to a
mean PTV radius of 2 cm, a diameter of 4 cm, and therefore a
gross lesion diameter of >3 cm when accounting for PTV mar-
gin. Therefore, the rate of local control exhibited in this series is
consistent in part with the larger size of lesion treated in compar-
ison with other series. In addition, patient selection factors may
constitute an important component of disease control outcomes,
as patients treated in the recurrent setting after prior intracranial
radiotherapy may represent a group with more aggressive biology
at baseline. The doses per fraction used in this series are lower
than those employed in some series, and may have contributed to
a more modest local control. Due to toxicity concerns in a largely
pre-treated cohort of patients (the majority having previously
undergone WBRT), this fractionation has been the institutional
preference.
Despite the possible adverse factors attributable to the patients
in this series, the use of HT in the focal treatment of intracra-
nial lesions was associated with acceptable intracranial disease
control, overall survival, and toxicity when compared with other
series using alternative modalities. Hypofractionated HT-based
SRS should be considered a viable option in the management of
brain metastases or resection cavities in the initial or recurrent set-
ting, particularly when the size of the target is not amenable to a
single fraction treatment. We propose that a fractionation schedule
of 25 or 27.5 Gy in five fractions is a reasonable approach provid-
ing adequate local control and toxicity profile in the proper setting
with results that are similar to those achieved by other series.
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